With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt
Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US, can unnerve sentiment, as seen when it reported Q2 results.
You may also be interested in...
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.
Heading into Phase III in 2019 is Lilly's dual agonist of GLP-1 and GIP, which has shown notable therapeutic effects on blood sugar and body weight in type 2 diabetics in a mid-stage clinical study. Meanwhile Lilly/Boehringer Ingelheim's SGLT2 inhibitor, empagliflozin, is being discussed with regulators with regard to its use in type 1 diabetics, an additional indication, following the release of full results from the EASE Phase III program.